Six patients with the rare genetic disorder Fabry disease have filed a lawsuit against Cambridge, MA-based biotech company Genzyme (NASDAQ:GENZ) and Mt. Sinai Medical School over the handling of a rationing system for Genzyme’s Fabry treatment, agalsidase beta (Fabrazyme), the online publication Pharmalot reported yesterday. Genzyme, which is being bought by the French drug giant Sanofi-Aventis (NYSE:SNY) for $20.1 billion, started rationing its Fabry therapy after a temporary closure in 2009 of its Allston, MA, plant where the treatment is made. Mt. Sinai, of New York, is named in the lawsuit because it licensed the treatment to Genzyme and “went along with the rationing plan,” Pharmalot wrote.
By posting a comment, you agree to our terms and conditions.